Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 17 August 2027
- Last conf. stmt
- 3 August 2026
Spero Europe Limited
- Incorporated
- 18 August 2015 (11 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Owned by
- Spero Therapeutics, Inc
- Accounts type
- Total exemption full
- Region
- Greater London
- Address
- 6th Floor One London WallLondonEC2Y 5EB
Officers 1 active
Officer details are public data from the Companies House register.
Director · Appointed 15 October 2015
Also at F2G Ltd · more companies
Dutch
Born June 1963 (63)
Officer history (5 former)
30 January 2026
2 July 2022
Resigned Parr, Thomas as Director
8 November 2019
15 April 2019
15 April 2019
5 October 2016
7 June 2016
15 October 2015
18 August 2015
18 August 2015
Appointed Parr, Thomas as Director
18 August 2015
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Spero Therapeutics, Inc
Corporate entity · Notified 17 June 2017
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Public Limited Company
Reg. no. 333220858
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 12 November 2026 | Total exemption full accounts | 31 December 2025 | — | |
| 15 July 2026 | Termination of appointment of a director | |||
| 29 October 2025 | Total exemption full accounts | 31 December 2024 | ||
| 12 August 2025 | Confirmation statement with no updates | 3 August 2025 | ||
| 30 September 2024 | Total exemption full accounts | 31 December 2023 |
Some other companies at this address
Other companies in this industry
Sandwich
Newcastle Upon Tyne
Edinburgh
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →